Your session is about to expire
← Back to Search
Selatogrel for Heart Attack (SOS-AMI Trial)
SOS-AMI Trial Summary
This trial will test if a new drug can help people recently discharged from the hospital with type 1 heart attacks who have other risk factors for heart disease.
SOS-AMI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 346 Patients • NCT03384966SOS-AMI Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on dialysis.My liver function is significantly impaired.I have had a stroke or a mini-stroke in the last 3 months.You have a long-term low platelet count (less than 100,000 platelets per cubic millimeter).I have severe blockage in multiple heart arteries and at least two major health issues like a previous heart attack, diabetes, kidney disease, or poor blood flow in my legs.I had a heart attack within the last 4 weeks.I am currently on a combination of blood thinners and antiplatelet medications.I have a history of serious bleeding or conditions that increase my risk.I am allergic to selatogrel or similar medications.My hemoglobin level is below 10 g/dL due to chronic anemia.
- Group 1: Selatogrel
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are being given the opportunity to participate in this research project?
"Recruitment for this trial is currently inactive. The study was originally posted on 8/14/2021, with the most recent update made on 11/15/2022. There are other research studies you may be eligible for; as of now, there are 373 clinical trials actively admitting patients with infarction and 1 study for Selatogrel looking for participants."
Is this a unique or innovative clinical trial?
"Selatogrel's clinical trials began in 2021, with the first study being sponsored by Idorsia Pharmaceuticals Ltd. That initial trial included 14000 patients. Selatogrel completed Phase 3 of its drug approval process and is now only undergoing one active trial, again sponsored by Idorsia Pharmaceuticals Ltd."
Is this trial widely available in North America?
"This clinical trial has 93 active medical sites, including CISSSL - Hopital Pierre-Le Gardeur in Terrebonne, Inova Heart & Vascular Institute in Falls Church, and Advanced Heart Care, LLC in Bridgewater."
Are there still available slots where people can enroll in this clinical trial?
"At present, this clinical trial is not recruiting patients. The study was first posted on August 14th, 2021 and was last updated on November 15th, 2022. For individuals seeking other studies, there are currently 373 trials actively recruiting patients for infarction and 1 Selatogrel trial also looking for participants."
Does Selatogrel put patients at risk?
"Selatogrel has received a 3 for safety from our team at Power. This is due to the fact that Selatogrel is in Phase 3 trials, which suggests that not only does some data support efficacy, but multiple rounds of data support safety."
Are there any other similar drugs to Selatogrel that have been trialed before?
"Currently, there is 1 clinical trial for Selatogrel that is still ongoing and in Phase 3. However, most of the research conducted on Selatogrel has taken place in 's-Hertogenbosch and British Columbia. In total, 314 different locations have been used to study Selatogrel."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger